BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Everest Medicines (Beijing) Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Everest Medicines (Beijing) Co.\,
  Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07122401-897@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:MT1013: Phase 3 readout est. (NCT07122401)
DESCRIPTION:MT1013\, phase 3\, Chronic Kidney Disease.\nStudy: Study of MT1
 013 for the Treatment of Patients With Secondary Hyperparathyroidism\nEsti
 mated primary completion: 26 November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/mt1013#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07122401
URL:https://assetmemo.bio/drug/mt1013#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577519-8692@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sumecigrel: Phase 3 readout est. (NCT06577519)
DESCRIPTION:Sumecigrel\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Efficacy and Safety Study of Vicagrel in Patients With Acute Coron
 ary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)\nEs
 timated primary completion: 30 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sumecigrel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06577519
URL:https://assetmemo.bio/drug/sumecigrel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102511-1049@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lerochol (Lerodalcibep): Phase 3 readout est. (NCT07102511)
DESCRIPTION:Lerochol (Lerodalcibep)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Study to Evaluate the Efficacy and Safety of Lerodalc
 ibep in Children 6 to 17 Years\, With Heterozygous FH\nEstimated primary c
 ompletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lerodalcibep#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07102511
URL:https://assetmemo.bio/drug/lerodalcibep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405970-5444@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Obinutuzumab beta (Bejescin): Phase 3 readout est. (NCT07405970)
DESCRIPTION:Obinutuzumab beta (Bejescin)\, phase 3\, Systemic Lupus Erythem
 atosus.\nStudy: A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythe
 matosus\nEstimated primary completion: December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obinutuzumab-beta-bejescin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07405970
URL:https://assetmemo.bio/drug/obinutuzumab-beta-bejescin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287126-13@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290616
DTEND;VALUE=DATE:20290617
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT05287126)
DESCRIPTION:Velsipity (etrasimod)\, phase 2\, Ulcerative Colitis.\nStudy: A
  Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Coli
 tis\nEstimated primary completion: 16 June 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05287126
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03950232-13@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290619
DTEND;VALUE=DATE:20290620
SUMMARY:Velsipity (etrasimod): Phase 3 readout est. (NCT03950232)
DESCRIPTION:Velsipity (etrasimod)\, phase 3\, Ulcerative Colitis.\nStudy: A
 n Extension Study for Treatment of Moderately to Severely Active Ulcerativ
 e Colitis\nEstimated primary completion: 19 June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03950232
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095868-2479@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:EVM14: Phase 1/2 readout est. (NCT07095868)
DESCRIPTION:EVM14\, phase 1/2.\nStudy: Evaluate the Safety\, Tolerability\,
  and Preliminary Efficacy of EVM14 Alone and in Combination in Patients Wi
 th Selected Solid Tumors\nEstimated primary completion: November 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/evm14#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07095868
URL:https://assetmemo.bio/drug/evm14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470879-13@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20300908
DTEND;VALUE=DATE:20300909
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT07470879)
DESCRIPTION:Velsipity (etrasimod)\, phase 2\, Ulcerative Colitis.\nStudy: A
  Study of How the Medicine Called "Etrasimod" Works in Children With the G
 ut Disease Called Ulcerative Colitis\nEstimated primary completion: 8 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etrasimod
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 70879
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775339-1049@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Lerochol (Lerodalcibep): Phase 3 readout est. (NCT07775339)
DESCRIPTION:Lerochol (Lerodalcibep)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Long-Term Efficacy and Safety of Lerodalcibep in Chil
 dren and Adolescents With Familial Hypercholesterolemia\nEstimated primary
  completion: 31 July 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lerodalcibep#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07775339
URL:https://assetmemo.bio/drug/lerodalcibep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
